Androgen and anti-androgen treatment modulates androgen receptor activity and DJ-1 stability

Prostate

Volumn 66, Issue 11, 2006, Pages 1177-1193

  Pitkänen Arsiola, Tiina ^a   Tillman, J Erin ^b,c   Gu, Guangyu ^b   Yuan, Jialing ^b   Roberts, Richard L ^e   Wantroba, Marcus ^f   Coetzee, Gerhard A ^f   Cookson, Michael S ^b   Kasper, Susan ^b,d  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e Owi Labs   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Androgen; Flutamide; Primary human epithelial cells; Probasin; Prostate cancer; PSA

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIESTROGEN; FLUTAMIDE; PROBASIN;

ARTICLE; CANCER SURVIVAL; CELL STRAIN LNCAP; DRUG EFFECT; EPITHELIUM CELL; GENE EXPRESSION REGULATION; HORMONE RESPONSE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN STABILITY; REPORTER GENE;

ANDROGEN ANTAGONISTS; ANDROGENS; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; DRUG STABILITY; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; EPITHELIAL CELLS; FLUTAMIDE; GENE EXPRESSION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICROSCOPY, ELECTRON; ONCOGENE PROTEINS; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 33746784275     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20450     Document Type: Article

References (41)

1. Huggins C, Hodges CV. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-297.
2. Brewster SF, Simons JW. Gene therapy in urological oncology: Principles, strategies and potential. Eur Urol 1994;25:177-182.
3. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP. Mutation of theandrogen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332:1393-1398.
4. Labrie F, Belanger A, Simard J, Labrie C, Dupont A. Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy. Cancer 1993;71:1059-1067.
5. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome. J Urol 1993;149:607-609.
6. Kelly WK, Slovin S, Scher HI. Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance. Urol Clin North Am 1997;24:421-431.
7. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T, Kallioniemi OP. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997;57:314-319.
8. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61:3550-3555.
9. Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001;61:2892-2898.
10. Balk SP. Androgen receptor as a target in androgen-independent prostate cancer. Urology 2002;60:132-138.
11. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
12. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D. Clucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000;6:703-706.
13. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999;59:2511-2515.
14. Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD. Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 2001;7:1273-1281.
15. Craft N, Shostak Y, Carey M, Sawyers C. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;5:280-285.
16. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, Hung MC. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000;60:6841-6845.
17. Torchia J, Glass C, Rosenfeld MG. Co-activators and co-repressors in the integration of transcriptional responses. Curr Opin Cell Biol 1998;10:373-383.
18. Suzuki H, Ueda T, Ichikawa T, Ito H. Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer 2003;10:209-216.
19. Kemppainen JA, Wilson EM. Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen receptor stabilization. Urology 1996;48:157-163.
20. Takahashi K, Taira T, Niki T, Seino C, Iguchi-Ariga SM, Ariga H. DJ-1 positively regulates the androgen receptor by impairing the binding of PIASx alpha to the receptor. J Biol Chem 2001;276:37556-37563.
21. Zhang ZF, Thomas TZ, Kasper S, Matusik RJ. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoid in vitro and in vivo. Endocrinology 2000;141:4698-4710.
22. Hayward S, Cox S, Mitchell I, Hallowes R, Deshpande N, Towler J. The effects of interferons on the activity of alpha-glycerolphosphate dehydrogenase in benign prostatic hyperplasia cells in primary culture. J Urol 1987;138:648-653.
23. Kasper S, Rennie PS, Bruchovsky N, Sheppard PC, Cheng H, Lin L, Shiu RPC, Snoek R, Matusik RJ. Cooperative binding of androgen receptors to two DNA sequences is required for androgen induction of the probasin gene. J Biol Chem 1994;269:31763-31769.
24. Tilley WD, Marcelli M, Wilson JD, McPhaul MJ. Characterization and expression of a cDNA encoding the human androgen receptor. Proc Natl Acad Sci USA 1989;86:327-331.
25. Henzel WJ, Billeci TM, Stults JT, Wong SC, Grimley C, Watanabe C. Identifying proteins from two-dimensional gels by molecular mass searching of peptide fragments in protein sequence databases. Proc Natl Acad Sci USA 1993;90:5011-5015.
26. Mann M, Hojrup P, Roepstorff P. Use of mass spectrometric molecular weight information to identify proteins in sequence databases. Biol Mass Spectrom 1993;22:338-345.
27. Yates JR III, Speicher S, Griffin PR, Hunkapiller T. Peptide mass maps: a highly informative approach to protein identification. Anal Biochem 1993;214:397-408.
28. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003;361:955-964.
29. Thomson AA, Cunha GR. Prostatic growth and development are regulated by FCF10. Development 1999;126:3693-3701.
30. Dalrymple S, Antony L, Xu Y, Uzgare AR, Arnold JT, Savaugeot J, Sokoll LJ, De Marzo AM, Isaacs JT. Role of notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells. Cancer Res 2005;65:9269-9279.
31. Yasunaga Y, Nakamura K, Ko D, Srivastava S, Moul JW, Sesterhenn IA, McLeod DG, Rhim JS. A novel human cancer culture model for the study of prostate cancer. Oncogene 2001;20:8036-8041.
32. McManaman JL, Zabaronick W, Schaack J, Orlicky DJ. Lipid droplet targeting domains of adipophilin. J Lipid Res 2003;44:668-673.
33. Xu Y, Iyengar S, Roberts RL, Shappell SB, Peehl DM. Primary culture model of peroxisome proliferator-activated receptor gamma activity in prostate cancer cells. J Cell Physiol 2003;196:131-143.
34. Yasunaga Y, Nakamura K, Ewing CM, Isaacs WB, Hukku B, Rhim JS. A novel human cell culture model for the study of familial prostate cancer. Cancer Res 2001;61:5969-5973.
35. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003;57:205-225.
36. Rowley DK, Tindall DJ. Responses of NBT-II bladder carcinoma cells to conditioned medium from normal urogenital sinus. Cancer Res 1987;47:2955-2960.
37. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang D.-E, Sar M, Gumerlock PH, de Vere White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen dependent human prostate cancer xenograft CWR22 and LNCaP Cells. Mol Endocrinol 1997;11:450-459.
38. Kasper S, Reunie PS, Bruchovsky N, Lin L, Cheng H, Snoek R, Dahlman-Wright K, Gustafsson JA, Shui R, Sheppard PC, Matusik RJ. Selective activation of the probasin androgen responsive region by steroid hormones. J Mol Endocrinol 1999;22:313-325.
39. Kotaja N, Aittomaki S, Silvennoinen O, Palvimo JJ, Janne OA. AR1P3 (androgen receptor-interacting protein 3) and other P1AS (protein inhibitor of activated STAT) proteins differ in their ability to modulate steroid receptor-dependent transcriptional activation. Mol Endocrinol 2000;14:1986-2000.
40. Junn E, Taniguchi H, Jeong BS, Zhao X, Ichijo H, Mouradian MM. Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase I activity and cell death. Proc Natl Acad Sci USA 2005;102:9691-9696.
41. Niki T, Takahashi-Niki K, Taira T, Iguchi-Ariga SM, Ariga H. DJBP: A novel DJ-1-binding protein, negatively regulates the androgen receptor by recruiting historic deacetylase complex, and DJ-1 antagonizes this inhibition by abrogation of this complex. Mol Cancer Res 2003;1:247-261.